Trial Profile
A Phase III, Open-Label, Multicenter Trial to Evaluate Ejection Fraction, End-Diastolic and End-Systolic Volumes, by Unenhanced and DEFINITY-Enhanced 2D-Echo and Magnetic Resonance Imaging
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 22 Dec 2020
Price :
$35
*
At a glance
- Drugs Perflutren (Primary)
- Indications Cardiovascular disorders
- Focus Diagnostic use; Registrational
- Acronyms BENEFIT 1 LVEF; BENEFIT1
- Sponsors Lantheus Medical Imaging
- 03 Feb 2020 According to a Lantheus Holdings media release, BENEFIT 1 is one of the two Phase 3 studies (BENEFIT 1 and BENEFIT 2) to evaluate LVEF measurement accuracy and reproducibility of DEFINITY contrast-enhanced and unenhanced echocardiography as compared to non-contrast cardiac magnetic resonance imaging (CMRI) used as the truth standard.When the data from BENEFIT 2 are available, the company will compile the data sets to analyze the full results of the trials.
- 03 Feb 2020 According to a Lantheus Holdings media release, although the endpoints for BENEFIT 1 were not met, the company will continue to analyze the BENEFIT 1 data.
- 03 Feb 2020 Primary endpoint (Demonstrate improvements in left ventricular ejection fraction measurement accuracy from unenhanced 2D echo imaging to imaging with DEFINITY contrast-enhanced 2D echo using cardiac magnetic resonance imaging as the truth standard) has not been met, according to a Lantheus Holdings media release.